Reach Us +44-7482878454
Assessment of a Microbicide Candidate among a Diverse Cohort of Urban Southern US Women and their Male Sexual Partners | OMICS International | Abstract
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Assessment of a Microbicide Candidate among a Diverse Cohort of Urban Southern US Women and their Male Sexual Partners

Paula Frew1,2,3,4*, Kimberly Parker5, Takeia Horton3,4, Brooke Hixson1,3,4, Lisa Flowers6, Frances Priddy1,7, Lisa Grohskopf8, Christine Mauck9 and Kimberly Workowski1,2,3

1Emory University School of Medicine, Department of Medicine, Division of Infectious Diseases, USA

2Emory Center for AIDS Research, USA

3The Hope Clinic of the Emory Vaccine Center, USA

4Emory University, Rollins School of Public Health, USA

5Texas Woman’s University, USA

6Emory University School of Medicine, Department of Obstetrics and Gynecology, USA

7International AIDS Vaccine Initiative, USA

8United States Centers for Disease Control and Prevention, USA


*Corresponding Author:
Paula M. Frew
Emory University, Department of Medicine
Division of Infectious Diseases
The Hope Clinic of the Emory Vaccine Center
603 Church Street, Decatur, GA 30030, USA
Tel: 404-712-8546
Fax: 404-712-9017
E-mail: [email protected]

Received Date: May 07, 2012; Accepted Date: June 28, 2012; Published Date: July 03, 2012

Citation: Frew P, Parker K, Horton T, Hixson B, Flowers L, et al. (2012) Assessment of a Microbicide Candidate among a Diverse Cohort of Urban Southern US Women and their Male Sexual Partners. J AIDS Clinic Res S4:004. doi:10.4172/2155-6113.S4-004

Copyright: © 2012 Frew P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: This mixed methods study reports on product acceptance from a Phase I clinical trial of a candidate non-nucleoside reverse transcriptase inhibitor (NNRTI) vaginal microbicide product (UC781). The product was evaluated in the context of a Phase I clinical trial in an area characterized by high HIV prevalence among minority women. The findings will inform the development of an acceptable microbicide that will address the needs of diverse women and their partners. Methods: This is a mixed methods study of 34 racially and ethnically diverse female participants and 10 male partners in Atlanta, Georgia. Chi-square tests for marginal homogeneity and kappa statistics were calculated to analyze differences between groups on product attributes and use intention. ANOVA was used to examine difference between the treatment groups. Qualitative data were analyzed via constant comparative methodology. Results: Thirty-four out of the original female cohort of 36 completed the questionnaire. Approval of future microbicide development was high at 91.2% (n=31) despite a lack of enthusiasm for the placebo and UC781 formulations. Overall female acceptability was correlated with personal protection motivation (r=1.00, p<0.001). African American women indicated greater likelihood of post-licensure microbicide use (χ2 (3)=7.9, p=0.048) and ascribed greater importance to its potential protection against HIV (χ2 (4)=18.7, p=0.001) and its potential for dual protection (protective against STIs and/or pregnancy) compared to white women (χ2 (4)=11.3, p=0.024). Men and women supported development in the form of an intravaginal ring or suppository. Men were more likely to encourage female adoption of the method if it afforded HIV protection (r=0.935, p=0.001). Conclusions: Although most women agreed that the development of a microbicide was an important endeavor, quantitative and qualitative data indicated they would not use placebo or UC781 due to the objectionable viscosity, odor, and color. Male partners felt the potential protective benefit of a future microbicide product was its most important feature.


Recommended Conferences
Share This Page